IL271211B2 - Acetyl-leucine for use in treatment of migraine - Google Patents

Acetyl-leucine for use in treatment of migraine

Info

Publication number
IL271211B2
IL271211B2 IL271211A IL27121119A IL271211B2 IL 271211 B2 IL271211 B2 IL 271211B2 IL 271211 A IL271211 A IL 271211A IL 27121119 A IL27121119 A IL 27121119A IL 271211 B2 IL271211 B2 IL 271211B2
Authority
IL
Israel
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
IL271211A
Other languages
English (en)
Hebrew (he)
Other versions
IL271211A (en
IL271211B1 (en
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL271211(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of IL271211A publication Critical patent/IL271211A/en
Publication of IL271211B1 publication Critical patent/IL271211B1/en
Publication of IL271211B2 publication Critical patent/IL271211B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271211A 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine IL271211B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
IL271211A IL271211A (en) 2020-01-30
IL271211B1 IL271211B1 (en) 2023-09-01
IL271211B2 true IL271211B2 (en) 2024-01-01

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271211A IL271211B2 (en) 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine

Country Status (25)

Country Link
US (1) US11471434B2 (cg-RX-API-DMAC10.html)
EP (1) EP3638370B1 (cg-RX-API-DMAC10.html)
JP (1) JP7130739B2 (cg-RX-API-DMAC10.html)
KR (1) KR102594130B1 (cg-RX-API-DMAC10.html)
CN (1) CN111093772B (cg-RX-API-DMAC10.html)
AU (1) AU2018284330B2 (cg-RX-API-DMAC10.html)
CY (1) CY1123860T1 (cg-RX-API-DMAC10.html)
DK (1) DK3638370T3 (cg-RX-API-DMAC10.html)
ES (1) ES2847169T3 (cg-RX-API-DMAC10.html)
GB (1) GB201709459D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20210108T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053089T2 (cg-RX-API-DMAC10.html)
IL (1) IL271211B2 (cg-RX-API-DMAC10.html)
LT (1) LT3638370T (cg-RX-API-DMAC10.html)
MA (1) MA49396B1 (cg-RX-API-DMAC10.html)
MD (1) MD3638370T2 (cg-RX-API-DMAC10.html)
MX (1) MX387909B (cg-RX-API-DMAC10.html)
PL (1) PL3638370T3 (cg-RX-API-DMAC10.html)
PT (1) PT3638370T (cg-RX-API-DMAC10.html)
RS (1) RS61481B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201912146RA (cg-RX-API-DMAC10.html)
SI (1) SI3638370T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100037T1 (cg-RX-API-DMAC10.html)
WO (1) WO2018229738A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201908087B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
ES2327684T3 (es) * 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
PT3600276T (pt) 2017-03-28 2023-07-11 Intrabio Ltd Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
US11793782B2 (en) 2017-10-18 2023-10-24 Intrabio Limited Therapeutic agents for neurodegenerative diseases
EP3697406A1 (en) 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Also Published As

Publication number Publication date
KR102594130B1 (ko) 2023-10-24
AU2018284330A1 (en) 2020-01-02
CA3067321A1 (en) 2018-12-20
JP2020526575A (ja) 2020-08-31
ES2847169T3 (es) 2021-08-02
MD3638370T2 (ro) 2021-04-30
CN111093772B (zh) 2023-11-03
RU2020100475A3 (cg-RX-API-DMAC10.html) 2021-10-22
DK3638370T3 (da) 2021-01-25
HUE053089T2 (hu) 2021-06-28
AU2018284330B2 (en) 2024-03-14
SI3638370T1 (sl) 2021-04-30
WO2018229738A1 (en) 2018-12-20
ZA201908087B (en) 2024-11-27
BR112019026660A2 (pt) 2020-07-14
HRP20210108T1 (hr) 2021-03-19
SG11201912146RA (en) 2020-01-30
RS61481B1 (sr) 2021-03-31
RU2020100475A (ru) 2021-07-14
MA49396A (fr) 2020-04-22
CN111093772A (zh) 2020-05-01
EP3638370B1 (en) 2020-11-11
SMT202100037T1 (it) 2021-03-15
US20200253905A1 (en) 2020-08-13
LT3638370T (lt) 2021-03-25
KR20210013518A (ko) 2021-02-04
MA49396B1 (fr) 2021-03-31
MX2019014784A (es) 2021-11-16
IL271211A (en) 2020-01-30
EP3638370A1 (en) 2020-04-22
PT3638370T (pt) 2021-01-26
JP7130739B2 (ja) 2022-09-05
CY1123860T1 (el) 2022-05-27
IL271211B1 (en) 2023-09-01
PL3638370T3 (pl) 2021-05-17
US11471434B2 (en) 2022-10-18
GB201709459D0 (en) 2017-07-26
MX387909B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
US20200147033A1 (en) Nutraceutical composition for pde4 inhibition, enhanced dopamine metabolism and long term potentiation
Ng et al. Potassium channel openers and prostacyclin play a crucial role in mediating the vasorelaxant activity of Gynura procumbens
CN104271141B (zh) 富含鞣花单宁提取物的组合物
JP2020522487A (ja) ストレス障害のホルモンカスケードを調節する組成物および方法
US20060233892A1 (en) Topiramate compositions for treatment of headache
Rivera-García et al. The resurgence of hallucinogen drugs in clinical research
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
Woolf et al. Nondrug interventions for treatment of hypertension
MX2024012638A (es) Composicion que comprende n-acetilcisteina, vitamina d y preferentemente glutation, usos de la misma, y composiciones farmaceuticas y nutraceuticas de los mismos
MX2022012693A (es) Composicion que comprende metilfolato.
HRP20210108T1 (hr) Liječenje migrene s acetil-leucinom
US11484523B1 (en) Compositions for prevention and treatment of symptoms associated with alcohol consumption
WO2002092112A1 (en) Oral supplement
FI3694505T3 (fi) Yhdiste ja koostumus käytettäväksi sellaisten keskushermoston sairauksien ennaltaehkäisevään ja/tai parantavaan hoitoon, jotka ovat tunnettuja neuronaalisen plastisuuden vähenemisestä, erityisesti tunnettuja synaptisen plastisuuden vähenemisestä
US20180055849A1 (en) Nutraceutical capsule and tablet formulations providing enhanced mental clarity, concentration and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal
RU2572720C1 (ru) Комплексное антиникотиновое средство
CN103392882A (zh) 防贫血茶叶
Sönmez et al. Effects of oral supplementation of mint extract on muscle pain and blood lactate
US7645766B1 (en) Method for treatment of depression and depressive mood disorders
US4609656A (en) Medical agent for improving and treating mental symptoms induced by cerebral disturbances
WO2006087420A3 (en) A method for treating heart failure
CA2385774A1 (en) Composition to reduce food cravings and supress the appetite
WO2006079999A2 (en) Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
RU2236230C2 (ru) Способ профилактики рецидивов при алкоголизме
Naidu et al. P2. 149 Efflcacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease